3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Kidney Transplantation
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Adenocarcinoma, Clear Cell
1
Interventions
pirtobrutinib
6
Cyclophosphamide
6
Mycophenolic Acid
5
fludarabine phosphate
4
fludarabine
4
Rituximab
4
Melphalan
4
Azacitidine
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Tacrolimus
3
Mesna
3
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Lenalidomide
2
Cyclosporine
2
Busulfan
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Bendamustine Hydrochloride
2
zanubrutinib
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
cedazuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Alemtuzumab
×
1 year
×
Clear all
No trials found.